MCIA Virtual Workshop: Tips for successfully engaging with Human Research Ethics Committee

This workshop is designed to provide a forum for participants from across the medicinal cannabis industry, and particularly medicinal cannabis companies and research organisations, to discuss approaches to successfully engaging with HREC in the area of clinical trials involving unregistered medicinal cannabis therapeutic goods.

MCIA is supporting this to assist in enabling and encouraging robust clinical research in the sector.

Date:        28 October 2022
Time:       11:00am – 1.00pm (AEST)
Virtual:    Zoom link will be provided when you register

The workshop will cover:

  • Sponsor obligations and responsibilities
  • Botanical drug product and quality control
  • Preclinical evidence
  • Trial design

Facilitator:

  • Dr Melinda Thompson, Head of Regulatory Affairs & Quality Systems Source Certain and Chair of MCIA Research Working Group

Presenters include:

  • Professor Andrew McLachlan, Head of School & Dean of Pharmacy, University of Sydney
  • Biljana Georgievska, EVP Commercial, Nucleus Network
  • Dr Anastasia Suraev, The Lambert Initiative

Please register below if you would like to attend and you will receive a confirmation email containing information about joining the meeting.

ACannabis 2023: Growing The Industry Through Research, Collaboration and Innovation.

ACannabis is back

ACannabis has established itself as a professional, credible industry event on the Australian medicinal cannabis calendar.  Speakers, partners and delegates continue to rate the conference highly for format, content and organisation and we can’t wait to come back face to face in 2023.

Continue reading “ACannabis 2023: Growing The Industry Through Research, Collaboration and Innovation.”

MCIA Networking Event: Understanding Clinical Trials and Insurance Requirements

Please join MCIA and industry colleagues for a fireside chat and networking function. Daniel Rooney (Insurance broker, Marsh) will be in conversation with Will Clarke (Underwriter, NewLine) to discuss Understanding Clinical Trials and Insurance Requirements. Will and Daniel will discuss the in’s and outs of clinical trials, where claims typically occur and how to make sure you have the right protection in place

Continue reading “MCIA Networking Event: Understanding Clinical Trials and Insurance Requirements”

ACannabis 2022 – Bridging the gap: evidence, confidence, access

ACannabis is back in 2022. With the theme, ‘Bridging the gap: evidence, confidence, access‘, ACannabis will be held over two jam packed days, Tuesday 15th March to Wednesday 16th March, and is the one location to stay up to date with all facets of the medicinal cannabis industry.
Due to the ever changing landscape, ACannabis 2022 will be a virtual conference and exhibition with a wide range of networking opportunities available. It will be immersive, engaging and deliver an:

Continue reading “ACannabis 2022 – Bridging the gap: evidence, confidence, access”

MCIA Industry Networking Event:  Insights into evolving medicinal cannabis export opportunities

Please join us for the inaugural MCIA networking event to socialise, celebrate and contribute ideas for developing future networking events! Each occasion will include a speaker and presentation on a topic of interest to the industry.

Continue reading “MCIA Industry Networking Event:  Insights into evolving medicinal cannabis export opportunities”

MCIA Exclusive Webinar – Latest FreshLeaf Analytics Report H2 2021

MCIA is excited to invite you to an exclusive webinar hosted by FreshLeaf Analytics and AJD Media to present the H2 2021 FreshLeaf Analytics Market Report.

This report will be the 7th major publication from FreshLeaf, who has been covering the Australian medical cannabis industry since 2017, and is the leading source of information, data and insight on the sector.

Continue reading “MCIA Exclusive Webinar – Latest FreshLeaf Analytics Report H2 2021”

Meeting Your Obligations – Supplying Medicinal Cannabis in Australia Workshop

Registration is now open for the TGA ‘Meeting Your Obligations – Supplying medicinal cannabis in Australia’ Workshop. MCIA has worked with TGA to deliver this workshop to assist members and others in the industry understand their obligations and specifically assist to understand the requirements for S3 over-the-counter (OTC) product registration requirements.

Continue reading “Meeting Your Obligations – Supplying Medicinal Cannabis in Australia Workshop”

ACannabis Evolve 2021 – Unlocking the Potential of Medicinal Cannabis

In launching ACannabis we noted that the medicinal cannabis industry is rapidly evolving, with many voices in the conversation. ACannabis is about harnessing the collective talent, knowledge and expertise that is critical to seize the opportunities in this exciting new industry which is providing an important new medicine for patients.

Read more on the ACannabis website or Register for ACannabis EVOLVE 2021 now

Continue reading “ACannabis Evolve 2021 – Unlocking the Potential of Medicinal Cannabis”

ACannabis – The Industry Led Australian Medicinal Cannabis Conference, 2020

ACannabis Conference

“ACannabis is the platform to gain a deep understanding of ground-breaking research, an inside perspective on global trends and a unique opportunity for the agritech and medtech sector to have the conversations required to leverage our advantages” Peter Crock, Chair Medicinal Cannabis Industry Australia

Continue reading “ACannabis – The Industry Led Australian Medicinal Cannabis Conference, 2020”

Medicinal Cannabis Industry Australia Launch endorsed by Government and Industry leaders

Around 70 members of parliament, government representatives, patient advocacy groups and industry participants gathered for the launch of the medicinal cannabis industry’s peak industry body – Medicinal Cannabis Industry Australia (MCIA).

Greg Hunt Minister for Health and Peter Crock Chair MCIA
Greg Hunt Minister for Health and Peter Crock Chair MCIA
Continue reading “Medicinal Cannabis Industry Australia Launch endorsed by Government and Industry leaders”